It is a fact that pharmaceutical production is facing major changes. One of the most important drivers of these changes is the new GMP Annex 1, which contains new guidelines for the manufacture of sterile medicinal products.

But how can requirements such as the elimination of GMP-critical interventions be implemented today and in the future? Barrier systems, robots and automated systems play a key role in meeting these requirements in production. But how can this be implemented in everyday production? What do these requirements mean for the production of the future?
How can these requirements actually be implemented in the production of small batches, such as personalized ATMPs, but also in larger quantities of conventional biologics?

Annex 1 - presents us with major challenges, but isn't it perhaps also the change for all those involved in the supply chain to think across processes and create a partnership between filling machine manufacturers and pharmacists?
We would like to take a closer look at these and other questions in the presentation “Setting sail for the requirements of Annex 1” together with Patrick Wieland from Bausch+Ströbel and Ruven Brandes.